Apellis Pharmaceuticals Inc — Balance Sheet (NASDAQ:APLS) | MetaTrader

Open full chart

Financials

Overview Relatórios Statistics Dividends

Quarterly Annual

Total assets 960.57 M881.76 M760.22 M788.73 M885.05 M1.08 B Total liabilities 756.01 M683.1 M590.35 M594.21 M656.51 M705.11 M Total equity 204.56 M198.66 M169.87 M194.52 M228.54 M370.15 M Total liabilities & shareholders' equities 960.57 M881.76 M760.22 M788.73 M885.05 M1.08 B Total debt —————— Net debt ——————

Notícias

Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y

H.C. Wainwright eleva preço-alvo da Apellis com base nas perspectivas da Syfovre

H.C. Wainwright raises Apellis stock price target on Syfovre outlook

Apellis Pharmaceuticals, Inc. (APLS) Q4 2025 Earnings Call Transcript

Lucro da Apellis Pharma superou projeções por $0,85; receita supera estimativas

Apellis Pharma earnings beat by $0.85, revenue topped estimates

Apellis Pharmaceuticals, Inc. (APLS) Surpasses Q4 Earnings and Revenue Estimates

Apellis apresenta crescimento de produtos e caminho para lucratividade

Apellis Q4 2025 slides: dual product growth, path to profitability

Apellis Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:APLS) 2026-02-24

Resultados da Apellis em foco: novo medicamento renal pode reacender o crescimento?

Apellis earnings on deck: Can new kidney drug revive growth momentum?